{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:38:48Z","timestamp":1793813928187,"version":"4.6.1"},"reference-count":226,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Alliance of Associations for Rheumatology"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1136\/ard-2022-223764","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T13:21:08Z","timestamp":1678972868000},"page":"30-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":739,"title":["EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct03942887","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Sanchez-Alamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-921X","authenticated-orcid":false,"given":"Alvise","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Blockmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia U","family":"Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raashid A","family":"Luqmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Mahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-7345","authenticated-orcid":false,"given":"Peter A","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7169-6936","authenticated-orcid":false,"given":"Aladdin J","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-6772","authenticated-orcid":false,"given":"Sara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-6667","authenticated-orcid":false,"given":"Chetan B","family":"Mukhtyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Musial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Price-Kuehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Segelmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y K Onno","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-7336","authenticated-orcid":false,"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-7091","authenticated-orcid":false,"given":"Gunnar","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-9172","authenticated-orcid":false,"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-3863","authenticated-orcid":false,"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223764_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of rheumatology\/european alliance of associations for rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of rheumatology\/european alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of rheumatology\/european alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib6","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jclinepi.2010.07.001","article-title":"Agree II: advancing Guideline development, reporting and evaluation in health care","volume":"63","author":"Brouwers","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/ard-2022-223764_bib9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/annrheumdis-2022-eular.3156","article-title":"POS0830 SYSTEMATIC literature review informing the 2022 update of the eular recommendations for the management of ANCA-associated vasculitis: focus on treatment strategies","volume":"81","author":"Schirmer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib10","doi-asserted-by":"crossref","unstructured":"Sanchez-Alamo B, Schirmer JH, Hellmich B, et al. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 2 - treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV. 2023.","DOI":"10.1136\/rmdopen-2023-003083"},{"key":"10.1136\/ard-2022-223764_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.40776","article-title":"Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Gopaluni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of rheumatology\/vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3899\/jrheum.200721","article-title":"CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update","volume":"48","author":"Mendel","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib15","first-page":"71","article-title":"A Dutch consensus statement on the diagnosis and treatment of ANCA-associated vasculitis","volume":"78","author":"Dirikgil","year":"2020","journal-title":"Neth J Med"},{"key":"10.1136\/ard-2022-223764_bib16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s13023-020-01621-3","article-title":"French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)","volume":"15","author":"Terrier","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1136\/ard-2022-223764_bib17","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/keaa073","article-title":"The nose is an organ too","volume":"59","author":"Mukhtyar","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.39104","article-title":"Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00393-008-0290-9","article-title":"Longitudinal effects of structured patient education programs for vasculitis patients","volume":"67","author":"Herlyn","year":"2008","journal-title":"Z Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/03009742.2021.1972534","article-title":"The impact of a structured one-day seminar on disease-specific knowledge, lifestyle habits and disease impairment in ANCA-associated vasculitis. Results of a randomized, controlled study","volume":"52","author":"Garbe","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib27","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jbspin.2019.12.005","article-title":"Predictors of fatal and non-fatal cardiovascular events in ANCA-associated vasculitis: data from the Toronto canvasc cohort","volume":"87","author":"Houben","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2022-223764_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.20433","article-title":"A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis","volume":"63","author":"Suppiah","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223764_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis Study Group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib33","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib34","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib35","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/annrheumdis-2016-210289","article-title":"EULAR\/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures","volume":"76","author":"Lems","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib36","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.27763","article-title":"Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades","volume":"63","author":"Holle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/rheumatology\/kev286","article-title":"Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort","volume":"55","author":"Schirmer","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/ndt\/gfy402","article-title":"Estimating the epidemiology of anti-neutrophil cytoplasm antibody-associated renal vasculitis and the role of histologic chronicity in predicting renal outcomes","volume":"34","author":"Kronbichler","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib40","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib41","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfab250","article-title":"Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"37","author":"Casal Moura","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2215\/CJN.14561119","article-title":"Developments in the histopathological classification of ANCA-associated glomerulonephritis","volume":"15","author":"van Daalen","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib43","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2215\/CJN.04800516","article-title":"Prognostic value of histologic classification of ANCA-associated glomerulonephritis","volume":"11","author":"Bj\u00f8rneklett","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib44","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","article-title":"Development and validation of a renal risk score in ANCA-associated glomerulonephritis","volume":"94","author":"Brix","year":"2018","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2022-223764_bib45","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/ndt\/gfu042","article-title":"Repeat protocol renal biopsy in ANCA-associated renal vasculitis","volume":"29","author":"Hruskova","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib46","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/ndt\/gfx248","article-title":"Vasculitis-when can biopsy be avoided?","volume":"32","author":"Jayne","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00000478-199006000-00006","article-title":"Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients","volume":"14","author":"Devaney","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ard-2022-223764_bib48","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1183\/09031936.97.10122738","article-title":"Efficacy of transbronchial biopsy in pulmonary vaculitides","volume":"10","author":"Schnabel","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1136\/ard-2022-223764_bib49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000449529","article-title":"Myeloperoxidase anti-neutrophil cytoplasmic antibody-positive interstitial pneumonia associated with granulomatosis with polyangiitis diagnosed by surgical lung biopsy","volume":"92","author":"Chino","year":"2016","journal-title":"Respiration"},{"key":"10.1136\/ard-2022-223764_bib50","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0003-4975(02)04027-4","article-title":"Role of thoracic surgery and interventional bronchoscopy in Wegener's granulomatosis","volume":"74","author":"Utzig","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"10.1136\/ard-2022-223764_bib51","first-page":"680","article-title":"Antineutrophil cytoplasmic antibody (ANCA) negative limited-form granulomatosis with polyangiitis of the lung diagnosed by the thoracoscopic lung biopsy","volume":"71","author":"Tomizawa","year":"2018","journal-title":"Kyobu Geka"},{"key":"10.1136\/ard-2022-223764_bib52","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib53","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.161224","article-title":"Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA) -associated vasculitis: the influence of ANCA subtype","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib54","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2214\/AJR.18.20967","article-title":"Chest high-resolution CT findings of microscopic polyangiitis: a Japanese first nationwide prospective cohort study","volume":"213","author":"Suzuki","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1136\/ard-2022-223764_bib55","first-page":"195","article-title":"Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis","volume":"36","author":"Baqir","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1136\/ard-2022-223764_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1378\/chest.117.1.117","article-title":"Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings","volume":"117","author":"Choi","year":"2000","journal-title":"Chest"},{"key":"10.1136\/ard-2022-223764_bib57","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2015.04.013","article-title":"Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: a long-term retrospective study on 42 patients","volume":"14","author":"Dunogu\u00e9","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223764_bib58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10334-012-0351-6","article-title":"Magnetic resonance imaging in patients with granulomatosis with polyangiitis (Wegener's) and subglottic stenosis","volume":"26","author":"Klink","year":"2013","journal-title":"MAGMA"},{"key":"10.1136\/ard-2022-223764_bib59","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/acr.23332","article-title":"Accuracy of magnetic resonance imaging for grading of subglottic stenosis in patients with granulomatosis with polyangiitis: correlation with pulmonary function tests and laryngoscopy","volume":"70","author":"Henes","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223764_bib60","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.ophtha.2013.12.003","article-title":"Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of systemic involvement","volume":"121","author":"Tan","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1136\/ard-2022-223764_bib61","first-page":"342","article-title":"Characterization of F-18 fluorodeoxyglucose PET\/CT in granulomatosis with polyangiitis","volume":"32","author":"Nelson","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1136\/ard-2022-223764_bib62","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12149-013-0769-6","article-title":"Integration of 2-deoxy-2- [18F] fluoro-D-glucose PET\/CT into clinical management of patients with Wege'er's granulomatosis","volume":"27","author":"Ozmen","year":"2013","journal-title":"Ann Nucl Med"},{"key":"10.1136\/ard-2022-223764_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12149-012-0675-3","article-title":"Evaluation of Wegener's granulomatosis using 18F-fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"27","author":"Ito","year":"2013","journal-title":"Ann Nucl Med"},{"key":"10.1136\/ard-2022-223764_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.md.0000158825.87055.0b","volume":"84","author":"Pagnoux","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2022-223764_bib65","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/rheumatology\/kez217","article-title":"Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis","volume":"58","author":"Quinn","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib66","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/rheumatology\/kev129","article-title":"Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience","volume":"54","author":"Terrier","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib67","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102618","article-title":"2020 international consensus on ANCA testing beyond systemic vasculitis","volume":"19","author":"Moiseev","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223764_bib69","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib70","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/ard.2010.130203","article-title":"Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?","volume":"69","author":"Holle","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ajkd.2005.05.003","article-title":"Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ancas in crescentic glomerulonephritis","volume":"46","author":"Rutgers","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2022-223764_bib72","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2022-223764_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-Wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2022-223764_bib74","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib75","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keaa805","article-title":"Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"60","author":"Papo","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib76","article-title":"International consensus on ANCA testing in eosinophilic granulomatosis with polyangiitis","volume":"25","author":"Moiseev","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard-2022-223764_bib77","article-title":"Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: A double-blind, randomized, controlled trial [abstract]","volume":"73","author":"Terrier","year":"2021","journal-title":"Arthritis & Rheumatology"},{"key":"10.1136\/ard-2022-223764_bib78","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102514","article-title":"Usefulness of vasculitis biomarkers in the era of the personalized medicine","volume":"19","author":"Csernok","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223764_bib81","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib82","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib83","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib84","doi-asserted-by":"crossref","DOI":"10.2196\/17231","article-title":"Clinical characteristics of an Internet-based cohort of patient-reported diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis: observational study","volume":"22","author":"Springer","year":"2020","journal-title":"J Med Internet Res"},{"key":"10.1136\/ard-2022-223764_bib85","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/acr.20605","article-title":"Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's)","volume":"63","author":"Clowse","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223764_bib86","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/art.22660","article-title":"Gonad evaluation in male systemic lupus erythematosus","volume":"56","author":"Soares","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib87","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3899\/jrheum.141104","article-title":"Leukemia and myelodysplastic syndrome in granulomatosis with polyangiitis: subtypes, clinical characteristics, and outcome","volume":"42","author":"Knight","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib88","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ijc.10444","article-title":"Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis","volume":"100","author":"Knight","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1136\/ard-2022-223764_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126016","article-title":"Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies","volume":"10","author":"Shang","year":"2015","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223764_bib91","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib92","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/acr2.11274","article-title":"Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody-associated vasculitis: systematic review and meta-analysis","volume":"3","author":"B\u00e9nard","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/03009742.2021.1926318","article-title":"Comparison of outcomes using the rituximab originator MabThera with the biosimilar truxima in patients with ANCA-associated vasculitis","volume":"51","author":"Antonelou","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib94","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10067-020-05261-7","article-title":"Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience","volume":"40","author":"Mittal","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib95","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3349\/ymj.2020.61.8.712","article-title":"Rituximab biosimilar prevents poor outcomes of microscopic polyangiitis and granulomatosis with polyangiitis as effectively as rituximab originator","volume":"61","author":"Kwon","year":"2020","journal-title":"Yonsei Med J"},{"key":"10.1136\/ard-2022-223764_bib96","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J Nephrol"},{"key":"10.1136\/ard-2022-223764_bib97","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib98","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfy075","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"33","author":"McAdoo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib99","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib100","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2022-223764_bib101","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1136\/ard-2022-223764_bib102","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib103","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib104","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","article-title":"Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1136\/ard-2022-223764_bib105","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib106","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib107","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-Term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib108","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1136\/ard-2022-223764_bib109","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019173","article-title":"Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study","volume":"99","author":"Waki","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2022-223764_bib110","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223764_bib111","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00296-017-3855-6","article-title":"Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"38","author":"Robson","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223764_bib112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"key":"10.1136\/ard-2022-223764_bib113","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib114","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s12879-019-4300-0","article-title":"Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"19","author":"Yamaguchi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1136\/ard-2022-223764_bib115","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/1756-185X.13662","article-title":"Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database","volume":"22","author":"Sakai","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib116","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","article-title":"Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis","volume":"57","author":"Walsh","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2022-223764_bib117","first-page":"493","article-title":"Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study","volume":"18","author":"Rifle","year":"1981","journal-title":"Proc Eur Dial Transplant Assoc"},{"key":"10.1136\/ard-2022-223764_bib118","first-page":"587","article-title":"Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis","volume":"6","author":"Mauri","year":"1985","journal-title":"Plasma Ther Transfus Technol"},{"key":"10.1136\/ard-2022-223764_bib119","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2022-223764_bib120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(12)80699-8","article-title":"A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group","volume":"20","author":"Cole","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2022-223764_bib121","first-page":"198","article-title":"Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis","volume":"148","author":"Guillevin","year":"1997","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1136\/ard-2022-223764_bib122","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/ajkd.2002.29874","article-title":"Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis","volume":"39","author":"Z\u00e4uner","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2022-223764_bib123","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-Term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2022-223764_bib124","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfq360","article-title":"Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis -- a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib125","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223764_bib126","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline","volume":"376","author":"Zeng","year":"2022","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223764_bib127","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib129","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2022-223764_bib130","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib131","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-Term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223764_bib132","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2022-223764_bib133","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.1780381116","volume":"38","author":"Guillevin","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib134","first-page":"567","volume":"18","author":"Guillevin","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"10.1136\/ard-2022-223764_bib136","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib137","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaa146.LB004","article-title":"LB004A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]","volume":"35","author":"Smith","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1136\/ard-2022-223764_bib138","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-Term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223764_bib139","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib140","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-Term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 117","key":"10.1136\/ard-2022-223764_bib141","first-page":"137","article-title":"Cost-Effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"37","author":"Montante","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102986","article-title":"The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum","volume":"20","author":"Kronbichler","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223764_bib143","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-cov-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib144","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- cov-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib145","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib146","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","article-title":"Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review","volume":"18","author":"Wijetilleka","year":"2019","journal-title":"Autoimmunity Rev"},{"key":"10.1136\/ard-2022-223764_bib147","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib148","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in wegener's granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib149","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223764_bib150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","article-title":"Maintenance of remission with leflunomide in wegener's granulomatosis","volume":"43","author":"Metzler","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib151","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1093\/rheumatology\/keab267","article-title":"The role of trimethoprim\/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis","volume":"60","author":"Monti","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib152","article-title":"Interventions for renal vasculitis in adults","volume":"1","author":"Walters","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2022-223764_bib153","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib154","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223764_bib155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (wegener's): impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2022-223764_bib156","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/rheumatology\/kex281","article-title":"Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data","volume":"56","author":"de Joode","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib157","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib158","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib159","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/rheumatology\/kez016","article-title":"Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification","volume":"58","author":"Deshayes","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib160","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6369814","article-title":"Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: A clinical long-term follow-up study","volume":"2018","author":"Salmela","year":"2018","journal-title":"Int J Nephrol"},{"key":"10.1136\/ard-2022-223764_bib161","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib162","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib163","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006083","article-title":"Clinical characteristics and outcome of spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity","volume":"96","author":"Solans-Laqu\u00e9","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2022-223764_bib164","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib166","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223764_bib167","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000500352","article-title":"Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis","volume":"49","author":"Vandenbussche","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1136\/ard-2022-223764_bib168","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib169","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223764_bib170","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ki.2009.218","article-title":"The clinical course of ANCA small-vessel vasculitis on chronic dialysis","volume":"76","author":"Lionaki","year":"2009","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2022-223764_bib171","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2215\/CJN.03190321","article-title":"Disease activity and adverse events in patients with ANCA-associated vasculitides undergoing long-term dialysis","volume":"16","author":"Kauffmann","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223764_bib172","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/rheumatology\/ken321","article-title":"Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis","volume":"47","author":"Gao","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib173","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (churg-strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: A randomized, controlled trial","volume":"69","author":"Puechal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib174","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (churg-strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2022-223764_bib175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the french vasculitis study group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2022-223764_bib176","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.23912","article-title":"Comparison of the Birmingham vasculitis activity score and the five-factor score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 550 patients from Spain (REVAS registry)","volume":"72","author":"Solans-Laqu\u00e9","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223764_bib177","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1093\/rheumatology\/keab027","article-title":"Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal","volume":"60","author":"Garcia-Vives","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib178","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/rheumatology\/keab514","article-title":"Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss)","volume":"61","author":"Sartorelli","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib179","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.autrev.2014.08.002","article-title":"Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, pan and MPA patients without poor-prognosis factors","volume":"13","author":"Samson","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223764_bib180","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib181","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223764_bib182","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (churg-strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib183","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a european multicenter observational study","volume":"74","author":"Bettiol","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib184","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","article-title":"Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial","volume":"58","author":"Puechal","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib185","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00296-021-04961-w","article-title":"A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis","volume":"41","author":"Philobos","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223764_bib186","first-page":"S52","article-title":"Churg strauss syndrome -- successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib187","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2022-223764_bib188","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1136\/ard-2022-223764_bib189","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1136\/ard-2022-223764_bib190","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib191","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","article-title":"Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Emmi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 124","key":"10.1136\/ard-2022-223764_bib192","first-page":"171","article-title":"Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort","volume":"38","author":"Doubelt","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib193","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223764_bib194","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/art.40538","article-title":"Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: subgroup analysis of nationwide prospective cohort studies","volume":"70","author":"Watanabe","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223764_bib195","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ancas predict relapses in ANCA-associated vasculitis patients after rituximab","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib196","article-title":"A personalized rituximab retreatment approach based on clinical and B-cell biomarkers in ANCA-associated vasculitis","volume":"12","author":"Arnold","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223764_bib197","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib198","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223764_bib199","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2022-223764_bib200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223764_bib201","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/rheumatology\/key394","article-title":"Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases","volume":"58","author":"Wijetilleka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223764_bib202","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-Sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-Sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch co-trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib204","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223764_bib206","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib207","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MPH.0000000000000606","article-title":"Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate","volume":"38","author":"Watts","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1136\/ard-2022-223764_bib208","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/annrheumdis-2017-212588","article-title":"Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question","volume":"77","author":"Winthrop","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib209","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00042560-200008010-00007","article-title":"Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS clinical Trials Group 268","volume":"24","author":"Para","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1136\/ard-2022-223764_bib210","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/323353","article-title":"Trimethoprim-Sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ","volume":"184","author":"Leoung","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1136\/ard-2022-223764_bib211","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199503163321101","article-title":"A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS clinical trials group","volume":"332","author":"Bozzette","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib212","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","article-title":"Atovaquone compared with dapsone for the prevention of pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. community program for clinical research on AIDS and the AIDS clinical trials group","volume":"339","author":"El-Sadr","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib213","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00296-021-04945-w","article-title":"Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids","volume":"42","author":"Jinno","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223764_bib214","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","article-title":"A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. the dutch AIDS treatment group","volume":"327","author":"Schneider","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223764_bib215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib216","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib217","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib218","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfac052","article-title":"Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS","volume":"37","author":"Stevens","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib219","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/annrheumdis-2020-219773","article-title":"EULAR December 2020 viewpoints on SARS-cov-2 vaccination in patients with rmds","volume":"80","author":"Bijlsma","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/annrheumdis-2021-221366","article-title":"2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19","volume":"81","author":"Alunno","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib221","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2006.060301","article-title":"Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who can not be treated with cyclophosphamide","volume":"66","author":"Stassen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib222","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0140-6736(90)92205-V","article-title":"Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre","volume":"336","author":"Tervaert","year":"1990","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223764_bib223","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223764_bib224","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223764_bib225","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","article-title":"Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis","volume":"26","author":"Mansfield","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2022-223764_bib226","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400387X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400387X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:20:40Z","timestamp":1749792040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672400387X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":226,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S000349672400387X"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223764","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}